The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

A Provo jury on Tuesday convicted former Santaquin nurse Meggan Sundwall of manslaughter and obstruction of justice, deciding she used insulin to kill her friend, Kacee Lyn Terry, in Highland in ...

The FDA has spent much of 2025 issuing warnings about a single, recurring problem with GLP-1 weight loss drugs: patients and ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...

ITV's Tonight programme has been told there are believed to be over one million performance-enhancing drug and anabolic ...

Testing showed one sample contained two synthetic stimulants with ecstasy-like properties, an agricultural weedkiller and an ...

According to the in-depth market research report published by MarkNtel Advisors, the Wearable Health Devices Market in GCC is projected to grow at a CAGR of around 14.7% during 2026–2032, reflecting ...

But without insulin the sugar can’t be used, so the starvation response continues, and the body resorts to burning fatty ...

Testing showed one sample contained two synthetic stimulants with ecstasy-like properties, an agricultural weedkiller and an ...

The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...